1. Allegretti JR, Barnes EL, Stevens B, et al. Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab. Dig Dis Sci 2017;62:1590–6.
2. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–25.
3. Chalhoub JM, Rimmani HH, Gumaste VV, Sharara AI. Systematic review and meta-analysis: Adalimumab monotherapy versus combination therapy with immunomodulators for induction and maintenance of remission and response in patients with Crohn‘s disease. Inflamm Bowel Dis 2017;23:1316–27.
4. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn‘s disease. Cochrane Database Syst Rev 2016;10:CD000545.
5. Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn‘s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017;390:2779–89.
6. Colombel J-F, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn‘s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 2015;41:734–46.
7. Connell WR, Kamm MA, Dickson M, Balkwill AM, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249–52.
8. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn‘s disease: an intervention study. Gastroenterology 2001;120:1093–9.
9. Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn‘s disease. Gastroenterology 2014;146:681–8.e1.
10. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485–9.
11. Khan N, Abbas AM, Lichtenstein GR, Loftus EV, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013;145:1007–15.e3.
12. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn‘s disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825–34.
13. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:36–41.e1.
14. Kucharzik T, Dignass A, Atreya R, Bokemeyer B, et al. S3-Leitlinie – Colitis ulcerosa, 2018. https://www.awmf.org/leitlinien/detail/ll/021-009.html (Zugriff am 28.06.2018).
15. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679–86.
16. McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis 2014;23:267–71.
17. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392–400.e3.
18. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015;110:1324–38.
19. Preiß JC, Bokemeyer B, Buhr HJ, et al. Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014 [Updated German clinical practice guideline on „Diagnosis and treatment of Crohn‘s disease“ 2014]. Z Gastroenterol 2014;52:1431–84.
20. Ramadas AV, Gunesh S, Thomas GAO, Williams GT, et al. Natural history of Crohn‘s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200–6.
21. Timmer A, Patton PH, Chande N, McDonald JWD, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;(5):CD000478.
22. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929–36.
23. Vermeire S, Noman M, van Assche G, Baert F, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn‘s disease. Gut 2007;56:1226–31.
24. Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am 2014;24:367–78.
25. Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn‘s disease. Clin Gastroenterol Hepatol 2018;16:542–9.e1.
26. Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn‘s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 2016;14:242–50.e1–2.
Dr. med. Katrin Hirschmann, Prof. Dr. med. Jörg Hoffmann, St. Marien- und St. Annastiftskrankenhaus, Medizinische Klinik I, Salzburgerstr. 15, 67067 Ludwigshafen, E-Mail: firstname.lastname@example.org